Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Nourish, an AI-assisted nutrition clinic, secured $100 million in Series C funding to scale a model treating chronic disease through behavior change and dietitian-led care rather than medication alone. The company addresses a critical gap in healthcare: chronic conditions develop through years of metabolic drift, yet most interventions remain reactive rather than preventive, with behavioral sustainability determining long-term outcomes.
Cala Health secured $50 million in growth capital to expand commercial access to the Cala kIQ System, an FDA-cleared wearable device that delivers personalized peripheral nerve stimulation to reduce hand tremors in essential tremor and Parkinson's disease. The device represents a shift toward precision, at-home neuromodulation therapy that addresses motor control dysfunction without systemic medication.
Fitness operators are repositioning from aesthetic-focused wellness toward evidence-based preventive health infrastructure as consumers arrive armed with biometric data and longevity markers. This shift reflects a fundamental realignment in how exercise environments function within the broader health economy, moving beyond lifestyle branding into clinical-adjacent intervention.
China has launched a standardized, competency-based education programme in longevity medicine for physicians, representing a systematic shift from reactive disease treatment to proactive healthspan management. This credential-granting initiative integrates geroscience, preventive care, digital technologies, and personalized interventions across multiple medical specialties to address age-related health challenges at scale.
Older adults frequently misjudge their own vision quality, reporting good sight despite objective testing that reveals significant impairment. This discordance between perceived and measured vision creates a critical gap in early detection, as self-assessment alone fails to identify declining visual function that accelerates age-related decline in other systems.
Adverse childhood experiences predict functional disability in older adults through two distinct pathways: increased depressive symptoms and reduced cognitive function. This longitudinal evidence from over a decade of follow-up demonstrates that early-life adversity creates measurable constraints on physical capability decades later, independent of current socioeconomic status.
Cerevance's Phase 3 trial completion for solengepras, a GPR6 receptor agonist, marks a shift away from dopamine-centric Parkinson's treatment toward modulation of separate movement-control pathways. This approach addresses a critical gap in current therapy: the unpredictable ON/OFF cycling that limits quality of life despite symptom control.
p75 neurotrophin receptor activation preserves the structural integrity of neuromuscular junctions and maintains muscle strength throughout aging. This mechanism represents a pathway through which neural-muscle communication can be sustained, directly opposing the decline in force production that typically accompanies advancing age.
AlzeCure's ACD137, a selective TrkA receptor modulator, demonstrates analgesic efficacy in preclinical models while showing signs of joint protection—a combination absent in broader NGF inhibitors. This represents a mechanistic shift toward pain management that may address both symptom and disease progression in osteoarthritis.
DEXA body composition scanning has moved from clinical obscurity into mainstream longevity medicine, but rapid commercialization has created a quality control problem. Fitnescity Health's Clinical Integrity Standard addresses this by establishing voluntary benchmarks for testing environment stability, quality assurance, and clinical oversight—critical factors for reliable longitudinal tracking.
CereVance completed enrollment of 341 participants in a Phase 3 trial testing solengepras, a non-dopaminergic GPR6 inhibitor for Parkinson's motor fluctuations. The drug targets OFF-time reduction through a mechanism distinct from conventional dopamine-based therapies, addressing a significant gap in current treatment options for advanced motor dysfunction.
Aging muscle stem cells lose their capacity to use glutamine for lipid synthesis through reductive TCA cycling, a metabolic pathway essential for activation. Restoring this pathway represents a tractable intervention point against age-related muscle loss and functional decline.